Breaking News: FDA Gives Fast Track Designation for Revolutionary Prostate Cancer Treatment!
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for PSMA-Targeted Radiopharmaceutical for the Treatment of Metastatic Prostate Cancer BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find,…